Table 1 Overview of study characteristics
From: Routinely collected patient data in neurology research: a systematic mapping review
Data Item | Category | Full Articles (n = 207, %) | Abstract Only (n = 179, %) |
|---|---|---|---|
Neurological Condition | Multiple Conditions | 4 (1·9) | 7 (3·9) |
Single Conditions: | |||
Multiple Sclerosis | 61 (29·5) | 78 (43·6) | |
Epilepsy/Seizure | 42 (20·3) | 21 (11·7) | |
Parkinson’s Disease | 15 (7·2) | 14 (7·8) | |
Headache (all) | 18 (8·7) | 12 (6·7) | |
Migraine only | 10 (4·8) | 6 (3·4) | |
Neurodegenerative Disorders | 6 (2·9) | 2 (1·1) | |
Neuromuscular Disorders | 5 (2·4) | 4 (2·2) | |
Other | 56 (27·1) | 41 (22·9) | |
Statistical Methodology | Descriptive | 127 (61·3) | 116 (64·8) |
Regression | 35 (16·9) | 33 (18·4) | |
Survival Analysis | 12 (5·8) | 8 (4·5) | |
Administrative Data Algorithm | 9 (4·3) | 6 (3·3) | |
Machine Learning | 5 (2·4) | 2 (1·1) | |
NLP | 5 (2·4) | 5 (2·8) | |
Propensity Scoring | 4 (1·9) | 4 (2·2) | |
ANOVA | 3 (1·4) | 1 (0·6) | |
Other | 7 (3·4) | 4 (2·2) | |
Study Objective | Characterisation of a clinical population | 46 (22·2) | 44 (24·6) |
Risk Factors | 42 (20·3) | 31 (17·3) | |
Drug Effectiveness | 26 (12·6) | 15 (8·3) | |
Prediction | 18 (8·7) | 13 (7·3) | |
Healthcare Utilisation | 13 (6·3) | 9 (5·0) | |
Diagnosis Validity | 13 (6·3) | 5 (2·8) | |
Prevalence | 9 (4·3) | 7 (3·9) | |
Drug Safety | 9 (4·3) | 5 (2·8) | |
Drug Adherence | 8 (3·9) | 8 (4·5) | |
Other | 24 (11·6) | 42 (23·5) | |
Data Type | Hospital Data | 91 (44·0) | 66 (36·9) |
Claims Data | 22 (10·6) | 44 (24·6) | |
Clinic Data | 30 (14·5) | 28 (15·6) | |
Multicentre Data | 23 (11·1) | 21 (11·7) | |
Veterans or Military Data | 13 (6·3) | 11 (6·2) | |
Primary Care Data | 16 (7·7) | 2 (1·1) | |
Pharmaceutical Data | 3 (1·5) | 6 (3·4) | |
Other | 9 (4·3) | 1 (0·6) | |
Location | USA | 112 (54·1) | 127 (70·9) |
Europe | 54 (26·1) | 30 (16·8) | |
Rest of World | 41 (19·8) | 22 (12·3) | |